These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30530971)

  • 1. In-Out-Test: A New Paradigm for Sorting the Wheat from the Chaff in Prodromal Alzheimer's Disease.
    Torrealba E; Garcia-Morales P; Cejudo JC; Diaz M; Rodriguez-Esparragon F; Fabre O; Mesa-Herrera F; Marin R; Sanchez-Garcia F; Rodriguez-Perez A; Gramunt N
    J Alzheimers Dis; 2019; 67(1):265-277. PubMed ID: 30530971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment.
    Giuffrè GM; Quaranta D; Citro S; Morganti TG; Martellacci N; Vita MG; Rossini PM; Calabresi P; Marra C
    J Alzheimers Dis; 2024; 100(2):713-723. PubMed ID: 38905044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort.
    Alegret M; Sotolongo-Grau O; de Antonio EE; Pérez-Cordón A; Orellana A; Espinosa A; Gil S; Jiménez D; Ortega G; Sanabria A; Roberto N; Hernández I; Rosende-Roca M; Tartari JP; Alarcon-Martin E; de Rojas I; Montrreal L; Morató X; Cano A; Rentz DM; Tárraga L; Ruiz A; Valero S; Marquié M; Boada M
    Alzheimers Res Ther; 2022 Mar; 14(1):43. PubMed ID: 35303916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
    Wagner M; Wolf S; Reischies FM; Daerr M; Wolfsgruber S; Jessen F; Popp J; Maier W; Hüll M; Frölich L; Hampel H; Perneczky R; Peters O; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Lewczuk P; Kornhuber J; Wiltfang J
    Neurology; 2012 Feb; 78(6):379-86. PubMed ID: 22238414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature.
    Xie J; Gabelle A; Dorey A; Garnier-Crussard A; Perret-Liaudet A; Delphin-Combe F; Bathsavanis A; Dauphinot V; Lehmann S; Mercier B; Desestret V; Roullet-Solignac I; Vighetto A; Krolak-Salmon P
    J Alzheimers Dis; 2014; 41(4):1109-16. PubMed ID: 24762946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.
    Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC
    Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.